transgender minors

A new medical study out of Finland has found that gender-dysphoric adolescents and young adults who were subjected to gender reassignment interventions had worse mental health outcomes than a control group that did not receive such bodily alterations.

The study tracked 2,083 people who had sought medical services for gender confusion between 1996 and 2019. The findings are quite specific. From, “Psychiatric Morbidity Among Adolescents and Young Adults Who Contacted Specialised Gender Identity Services in Finland in 1996-2019,” just published in Acta Paediatrica (my emphases, citations omitted):

Gender-referred adolescents showed significantly higher psychiatric morbidity than controls both before (45.7% vs. 15.0%) and ≥ 2 years after referral (61.7% vs. 14.6%). Those referred after 2010 had greater psychiatric needs than earlier cohorts, both before (47.9% vs. 15.3%) and ≥ 2 years after (61.3% vs. 14.2%) referral. Among adolescents who underwent medical gender reassignment, psychiatric morbidity increased markedly during follow-up — rising from 9.8% to 60.7% in feminising gender reassignment. After adjusting for prior psychiatric treatment, all gender-referred adolescents had similarly elevated risks of psychiatric morbidity, with hazard ratios approximately three times higher than female controls and five times higher than male controls.

But what about previous studies that gender ideologues often cite to justify puberty blockers and mastectomies for underage patients? They were inadequate to the task at hand:

The first gender “detransitioner” medical-malpractice case to go to trial resulted in a $2 million dollar verdict against the medical professionals who approved a double mastectomy for the plaintiff, Fox Varian, in 2019 when she was only 16. From the Epoch Times story: A jury on Jan. 30 found a psychologist and surgeon liable for malpractice after they supported and performed breast removal surgery on a 16-year-old girl who at the time identified as transgender. Fox Varian, now 22 and no longer identifying as transgender, was awarded $2 million in damages, with $1.6 million for past and future pain and suffering, and another $400,000 for future medical expenses. The jury found that in many respects the surgeon and psychologist had Read More ›

The New England Journal of Medicine continues to besmirch its once august reputation by pushing ideology rather than medical science when discussing our nation’s most contentious social issues. This is particularly true about so-called gender-affirming care for minors experiencing gender confusion. Even as repeated medical studies undercut the ideological narrative that puberty blockers, hormones, and even surgeries are the best means of caring for dysphoric children — and as country after country severely restricted those interventions — (with the exception of an unsubstantive criticism of the Cass Review) articles in the NEJM on the question usually pretend that the pushback never happened.

Now, the editors have done it again, publishing an article by Scott Skinner-Thompson, an LGBT activist law professor from the University of Colorado, Boulder, criticizing the Supreme Court for allowing Tennessee to legally prevent such interventions in children. The pretense begins with the headline, “The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors.” To the contrary, Tennessee and other jurisdictions that have enacted such laws have done so to protect trans minors from potentially irreversible harm, in the knowledge that most gender dysphoric minors overcome their confusion by the time they reach adulthood.

Then, Skinner-Thompson leans on clearly ideological opinions by medical associations, despite at least one of which (WPATH) having been substantively discredited:

On June 18, 2025, the U.S. Supreme Court upheld Tennessee’s ban on gender-affirming hormonal treatment for transgender minors against an Equal Protection Clause challenge in United States v. Skrmetti. Transgender adolescents who need these medical interventions but live in one of the many states that ban them may need to look elsewhere for care. Nearly every major relevant U.S. health care organization has concluded that the prescription of hormones and puberty blockers for treating gender dysphoria in transgender adolescents is often medically appropriate in that it can improve mental health and well-being, whereas untreated gender dysphoria can lead to depression, anxiety, and suicidality.